Immutep Ltd. ADR
Immutep Ltd. ADR is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases. The company’s programs are built around LAG-3, an immune-regulating pathway used to modulate how the body’s immune system responds to disease. Its current pipeline includes product candidates such as eftilagimod alfa, IMP761, leramilimab, and GSK’781, which are being studied across multiple therapeutic areas. Immutep Ltd. ADR operates in the biotechnology segment of the healthcare market, where it contributes to the development of next-generation biologic treatments designed to address unmet medical needs. The company is headquartered in Sydney, Australia, and its work is centered on advancing specialized immunology-based therapies for use in oncology and autoimmune care.
$3.20
-$0.01 (-0.31%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-560.50% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
ROIC dropped from -22.23% to -103.00%, capital efficiency is deteriorating. Negative free cash flow of -A$56M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
A$15M
Net Income (TTM)
-A$79M
▼ -183.3% YoY
Op. Margin
-560.50%
ROIC
-103.00%
▼ -80.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-A$56M
▼ -137.2% YoY
Op. Cash Flow (TTM)
-A$56M
▼ -137.4% YoY
Net Debt
-A$68M
Net Cash Position
Cash & Equiv.
A$69M
3Y CAGR: +340.4%
Continue Research
Is Immutep Ltd. ADR (IMMP) overvalued?
Immutep Ltd. ADR (IMMP)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Immutep Ltd. ADR scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Immutep Ltd. ADR a high-quality business?+
Immutep Ltd. ADR scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -560.5% operating margin and a -103.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Immutep Ltd. ADR a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh IMMP's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.